Penumbra, Inc. (FRA:0P8)

Germany · Delayed Price · Currency is EUR

252.40

+8.70 (3.57%)

At close: Dec 4, 2025

8.51% (1Y)

Market Cap	9.90B
Revenue (ttm)	1.14B
Net Income (ttm)	139.80M
Shares Out	n/a
EPS (ttm)	3.53
PE Ratio	70.80
Forward PE	63.32
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	4
Open	244.00
Previous Close	243.70
Day's Range	244.00 - 253.20
52-Week Range	193.10 - 291.60
Beta	n/a
RSI	62.68
Earnings Date	Feb 23, 2026

About Penumbra

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDW... [Read more]

Industry Surgical and Medical Instruments and Apparatus

Founded 2004

Employees 4,500

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 0P8

Full Company Profile

Financial Performance

In 2024, Penumbra's revenue was $1.19 billion, an increase of 12.86% compared to the previous year's $1.06 billion. Earnings were $14.01 million, a decrease of -84.59%.

Financial numbers in USD Financial Statements

News

There is no news available yet.